ClinicalTrials.gg
RecruitingNCT05701293CURRENTUpdated Jul 20, 2023

A ProspeCtive mUlticenteR Investigation on RENzar Stent Safety and Efficacy in the Treatment of Patients With Femoro-popliteal Disease in Tuscany (CURRENT Registry)

An observational study in Peripheral Arterial Disease, sponsored by Azienda Ospedaliera Universitaria Senese. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-20.

Sponsored by Azienda Ospedaliera Universitaria Senese · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2023, 2 years 11 months ago, but the record still lists the study as recruiting.
  • Started Dec 2022; still recruiting 3 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 78 studies in Peripheral Arterial Disease with a site in Italy — 16 open to participants now, 21 under way, 2 of them phase 3. Peripheral Arterial Disease · Italy.

Planned enrollment
25th of 36
100 · median 204
Started
2022
with 3 others
Observational
36 of 78
10 open now
Primary completion
2023-12
later than 0 of 20 live
Registered
60th of 78
by date

Among the 78 studies in Peripheral Arterial Disease with a site in Italy, this one is the 25th largest by planned enrollment of the 36 observational ones that give a count, is one of 4 that started in 2022, is one of 36 observational ones, reaches primary completion later than 0 of the 20 other live ones, and was the 60th registered.

Peripheral Arterial Disease

1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

16 of the 78 studies in Peripheral Arterial Disease with a site in Italy are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies in Peripheral Arterial Disease with a site in Italy, or all of them as a file.
02

Study summary

CURRENT Registry is a physician-initiated prospective, multicenter, post-market, single-arm study with a plan to include approximately 100 patients eligible to be treated with RenzanTM Peripheral Stent System.

Read the detailed description

In the last years, most of the technical evolution of materials dedicated to the treatment of femoropopliteal disease has been focused on drug-eluting technologies. However, in very complex lesions drug-coated balloons seems to be less efficient, leading to a high rate of bailout stenting with bare metal stents. Drug-eluting stents have raised expectation, providing structural scaffolding of the artery and active pharmacological treatment of the target lesion. Available evidence from the literature does not always seem to support this hypothesis.

Still, a lot of rumours have been generated on the potential local and systemic toxicity of paclitaxel.

As a consequence, in complex lesion rather than Drug Coated Balloon and Drug Eluting Stent it seems that there is need of a modern generation of nitinol stents with high Radial Resistive Force, low chronic outward forces and high fracture resistance.

The device under investigation is the Renzan™ Peripheral Stent System from Terumo MicroVention Inc. (35 Enterprise, Aliso Viejo, California 92656, USA) .

The System consists of a self-expanding nitinol stent pre-mounted on the distal portion of a rapid exchange (RX) delivery catheter. The stent is made of a nickel-titanium alloy with radiopaque markers on each end of the stent. The nitinol stent is constructed from 2 layers of tubular braided nitinol wire mesh. The outer layer consists of nitinol wire braided into a closed cell structure with flared ends. The inner layer consists of nitinol wire braided into a closed cell structure with micro sized pores. The delivery catheter has a rapid exchange port designed to allow coaxial passage of a 0.46mm (0.018") or smaller guide wire in diameter. The stent is capable of being recaptured when a minimum of 20mm of stent length remains inside the catheter.

03

Conditions studied

  • Peripheral Arterial Disease

Keywords

  • peripheral arterial disease
  • chronic limb threatening ischemia
  • endovascular treatment
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with a diagnosis of Lower Extremity Artery disease needing for endovascular treatment

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years.
  2. Subject must provide written prior to the treatment of the target lesion.
  3. Subject must be willing to comply with the specified follow-up evaluation schedule.
  4. Subject with Rutherford-Becker clinical classification category 2 to 5, with a resting ankle-brachial index (ABI) ≤ 0.9.
  5. Common femoral, superficial femoral and/or popliteal artery lesion with > 50% stenosis or total occlusion.
  6. Stenotic or occluded lesion(s) within the same vessel with no length limits.
  7. De novo or restenotic/occluded lesion(s) including in-stent restenosis, with reference vessel diameter (RVD) ≥ 4.0 mm and ≤ 8.0 mm by visual assessment and no length limits.
  8. Multiple RENZAN stents could be deployed with a mandatory overlap of 0.5-1 cm.
  9. A patent inflow artery free from the significant lesion (≥50% stenosis) as confirmed by angiography (treatment of target lesion acceptable after successful treatment of ipsilateral iliac lesions); Successful ipsilateral iliac artery treatment is defined as the attainment of residual diameter stenosis ≤30%, either with PTA or stenting.
  10. The target lesion(s) can be successfully crossed with a guide wire and dilated up to 1:1 to the proposed stent to be implanted (as per the operator's assessment).
  11. At least one patent native outflow artery (anterior or posterior tibial or peroneal), free from significant (≥50%) stenosis (as confirmed by angiography), that has not previously been revascularized. The remaining outflow arteries requiring treatment during the same procedure may be treated

Exclusion criteria

Exclusion Criteria:

  1. Subject has Rutherford-Becker classification category 6.
  2. Treatment of lesions requiring the use of adjunctive debulking devices.
  3. Use of drug-eluting balloon or stent
  4. Inadequate vessel preparation not achieving a diameter of 1:1 to the stent to be implanted (with ≤20% residual stenosis, as per operator's assessment).
  5. Concomitant use of different stent platforms
  6. Any significant vessel tortuosity or other parameters prohibiting access to the lesion and/or preventing the stent delivery.
  7. Subject with coronary intervention performed less than 90 days prior to or planned within 30 days after the treatment of the target lesion.
  8. Known allergies or intolerance to nitinol (nickel titanium).
  9. Any or known unresponsiveness to dual antiplatelet therapy (DAPT) or anticoagulation therapy.
  10. Presence of acute thrombus prior to crossing the lesion.
  11. Thrombolysis of the target vessel within 72 hours prior to the index procedure
  12. Thrombophlebitis or deep venous thrombus, within the previous 30 days.
  13. Subject receiving dialysis within the previous 30 days.
  14. Stroke within the previous 90 days.
  15. Subject is pregnant or of
  16. Subject has a of less than 1 year.
  17. Subject is participating in an study that has not reached the primary endpoint at the time of study screening.
  18. Only one patent outflow artery, with significant stenosis (≥50%) (as confirmed by angiography)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • LEAD patients undergoing endovascular treatment with implantation of Renzan stent

    Procedure: Endovascular implantation of Renzan Stent

Interventions

  • ProcedureEndovascular implantation of Renzan Stent

    Endovascular treatment of LEAD patients with Renzan Stent

06

What researchers measure

Primary outcomes

  1. Primary Safety endpoint [composite]

    Death + target lesion revascularization (TLR) + Major Amputation (above the ankle)

    Time frame: 30 days after procedure

  2. Primary Efficacy endpoint

    Primary patency of the artery at 12 months, defined as no evidence of occlusion within the originally treated lesion based on Color Flow Doppler ultrasound in the absence of target lesion revascularization (TLR)

    Time frame: 12 months

Secondary outcomes

  1. Device Success

    Successful device deployment according to Instruction For Use.

    Time frame: Intraoperative

  2. Technical Success

    Achievement of a final target lesion residual diameter stenosis of \<30% based on angiography.

    Time frame: Intraoperative

  3. Procedural Success

    Technical and device success without procedural complication.

    Time frame: Intraoperative

  4. Any death

    Cardiovascular death and non-cardiovascular death

    Time frame: 1, 6, 12 24 and 36 months

  5. Clinically-driven Target Lesion Revascularization (CD-TLR)

    Any TLR associated with deterioration of patient's Rutherford category and/or increase in size of pre-existing ischemic wounds and/or occurrence of new wounds.

    Time frame: 1, 6, 12 24 and 36 months

  6. Patency of Target lesion

    Defined as no evidence of restenosis or occlusion within the originally treated lesion based on a Color Flow Doppler ultrasound in the absence of target lesion revascularization (TLR). Occlusion and restenosis were defined as no color flow or an increase in peak systolic velocity ratio (PSVR) of ≥ 2.4 when compared to the proximal normal segment, respectively.

    Time frame: 1, 6, 12 24 and 36 months

  7. Limb Ischemia Improvement

    Improvement in the Rutherford-Becker Clinical Improvement Scale of greater than or equal to 1. -Rutherford-Becker Classification: 0 Asymptomatic 1. Mild claudication 2. Moderate claudication 3. Severe claudication 4. Ischemic rest pain 5. Minor tissue loss 6. Major tissue loss

    Time frame: 1, 6, 12 24 and 36 months

  8. MAE (Major Adverse Event)

    a composite rate of: * cardiovascular death * procedure-related arterial rupture * acute limb ischemia * stent thrombosis * clinically apparent distal embolization * target limb amputation * procedure-related bleeding event requiring transfusion

    Time frame: 1, 6, 12 24 and 36 months

  9. Index Limb Amputation

    Amputation above the ankle.

    Time frame: 1, 6, 12 24 and 36 months

  10. Stent deployment performance evaluation

    Operators feedback on: Pushability/Trackability, Deployment, Visibility and Precise Placement -High, Moderate and Low

    Time frame: Intraoperative

07

Study locations

1 of 1 sites recruiting
  • University of Siena
    Siena, 53100, Italy
    Recruiting
    • Edoardo Pasqui, MD · Contact00390577585127
    • Raffaele Pulli, MD · Principal investigator
    • Stefano Michelagnoli, MD · Principal investigator
    • Leonardo Ercolini, MD · Principal investigator
    • Francesco Listro, MD · Principal investigator
    • Federico Filippi, MD · Principal investigator
    • Massimo Pieraccini, MD · Principal investigator
    • Giovanni Credi, MD · Principal investigator
    • Alessio Auci, MD · Principal investigator
    • Claudio Invernizzi, MD · Principal investigator
    • Roberto Arpesani, MD · Principal investigator
    • Raffaella Berchiolli, MD · Principal investigator
    • Roberto Lorenzoni, MD · Principal investigator
    • Marco Comeglio, MD · Principal investigator
    • Pierfrancesco Frosini, MD · Principal investigator
    • Giancarlo Palasciano, MD · Principal investigator
08

References and documents

Publications

  • Conte MS, Bradbury AW, Kolh P, White JV, Dick F, Fitridge R, Mills JL, Ricco JB, Suresh KR, Murad MH; GVG Writing Group. Global vascular guidelines on the management of chronic limb-threatening ischemia. J Vasc Surg. 2019 Jun;69(6S):3S-125S.e40. doi: 10.1016/j.jvs.2019.02.016. Epub 2019 May 28. Erratum In: J Vasc Surg. 2019 Aug;70(2):662. doi: 10.1016/j.jvs.2019.06.102. PubMed 31159978 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2022 (actual). Primary completion is estimated for Dec 2023, 12 months after the start.

Of 138 non-industry observational studies under Peripheral Arterial Disease, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 116. This study's planned 12 months is below that.

Counting every sponsor, half of 196 studies reached it within 36 months; a quarter within 22 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2023
First posted
Jan 27, 2023
StartActual
Dec 1, 2022
Primary completionEst.
Dec 1, 2023
CompletionEst.
Dec 1, 2026
Last update
Jul 20, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05701293
Lead sponsor
Azienda Ospedaliera Universitaria Senese
Collaborators
University of Florence
Responsible party
Gianmarco de Donato (Professor, University of Siena) — Principal investigator
First posted
Jan 27, 2023
Start date
Dec 1, 2022
Primary completion
Dec 1, 2023 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Jul 20, 2023

Study contacts

Gianmarco de Donato, MD
Contact
dedonato@unisi.it
00390577585123

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion